8-K - Denali Therapeutics Inc. | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

Denali Therapeutics Inc. received $200.0 million in gross proceeds from Royalty Pharma on March 27, 2026, following the accelerated FDA approval of tividenofusp alfa.

Key Takeaways

1The company received $200.0 million in gross proceeds from Royalty Pharma on March 27, 2026.

2The funding followed the accelerated FDA approval of tividenofusp alfa on March 24, 2026.

3The proceeds are related to the closing of transactions under a synthetic royalty funding agreement.

4The agreement was previously disclosed in a Form 8-K filed on December 4, 2025.

Current Report Details

Event Type

Financing

Regulation Fd

Disclosure

Mandatory

Variant

8-K

Items Reported

2.03

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information contained in Item 1.01 of the

Financing

7.01

below, is hereby incorporated by reference into this Item 2.03 in its entirety. Item 7.01 Regulation FD Disclosure. Royalty Agreement Closing and Funding On Mar

Regulation Fd

$200.0M

Transaction Details

Material Agreement

Agreement: synthetic royalty funding agreement
Parties: Denali Therapeutics Inc., Royalty Pharma

•$200.0 million gross proceeds received on March 27, 2026
•Closing followed FDA accelerated approval of tividenofusp alfa on March 24, 2026

Exhibits (1)

8-K